Palatin Technologies Inc (PTN)

Currency in USD
22.22
+1.67(+8.13%)
Closed·
22.22+0.36(+1.65%)
·
PTN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.8422.36
52 wk Range
1.7531.00
Key Statistics
Prev. Close
20.55
Open
22.36
Day's Range
20.84-22.36
52 wk Range
1.75-31
Volume
5.42K
Average Volume (3m)
18.15K
1-Year Change
114.686%
Book Value / Share
6.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PTN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Palatin Technologies Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Palatin Technologies Inc Earnings Call Summary for Q2/2026

  • Palatin Technologies reported Q2 2026 revenue of $116,000 (up from $0 prior year) with a net loss of $7.3 million ($2.86 per share) and increased operating expenses of $7.4 million.
  • The company maintains a cash position of $14.5 million as of December 31, 2025, with runway extending beyond March 2027 despite a 2.24% premarket stock decline.
  • Palatin plans to submit an IND application for its lead oral molecule PL7737 in H1 2026, with phase 1 trials to follow and potential combination therapies with GLP-1 treatments.
  • Revenue forecasts remain cautiously optimistic at $8.85 million for FY2026 and $10 million for FY2027, focusing on melanocortin-4 receptor agonists for rare obesity disorders.
Last Updated: 2026-02-17, 11:44 a/m
Read Full Transcript

Compare PTN to Peers and Sector

Metrics to compare
PTN
Peers
Sector
Relationship
P/E Ratio
−3.7x−1.3x−0.4x
PEG Ratio
−0.04−0.090.00
Price/Book
3.1x5.2x2.6x
Price / LTM Sales
4.0x9.4x3.1x
Upside (Analyst Target)
138.5%217.1%47.4%
Fair Value Upside
Unlock9.4%7.0%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 17, 2026
EPS / Forecast
-2.86 / -0.33
Revenue / Forecast
116.04K / --
EPS Revisions
Last 90 days

PTN Income Statement

People Also Watch

0.72
DLXY
-5.21%
0.37
ITOC
+23.36%
0.376
HCWB
-8.31%

FAQ

What Is the Palatin Tech (PTN) Stock Price Today?

The Palatin Tech stock price today is 22.22 USD.

What Stock Exchange Does Palatin Tech Trade On?

Palatin Tech is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Palatin Tech?

The stock symbol for Palatin Tech is "PTN."

What Is the Palatin Tech Market Cap?

As of today, Palatin Tech market cap is 35.53M USD.

What Is Palatin Tech's Earnings Per Share (TTM)?

The Palatin Tech EPS (TTM) is -7.93.

From a Technical Analysis Perspective, Is PTN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Palatin Tech Stock Split?

Palatin Tech has split 1 times.

How Many Employees Does Palatin Tech Have?

Palatin Tech has 29 employees.

What is the current trading status of Palatin Tech (PTN)?

As of Apr 27, 2026, Palatin Tech (PTN) is trading at a price of 22.22 USD, with a previous close of 20.55 USD. The stock has fluctuated within a day range of 20.84 USD to 22.36 USD, while its 52-week range spans from 1.75 USD to 31.00 USD.

What Is the PTN After Hours Price?

PTN's last after hours stock price is 22.22 USD, the stock has decreased by 0.36, or 1.65%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.